Abbott Expands Cardiac Arrhythmias Portfolio with FDA Clearance of Advanced Mapping Catheter

ABBOTT PARK, Ill., May 3, 2018 — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™. Advisor HD Grid employs a new design that allows physicians to see things differently, capturing and analyzing data in a novel manner to create highly detailed maps of the heart that better differentiate healthy from unhealthy tissue.

MRA vs CTA for evaluating pulmonary embolism: Does the chosen modality impact downstream imaging utilization?

Example of spectral, or dual-energy CT, confirming a pulmonary embolism (PE). Image courtesy of Philips Healthcare

Example of spectral, or dual-energy CT, confirming a pulmonary embolism (PE). Image courtesy of Philips Healthcare

MR angiography (MRA) is a relatively new alternative to CT angiography (CTA) for the evaluation of suspected pulmonary embolism (PE) and it even has one major advantage over CTA: it does not expose patients to ionizing radiation.

Women underrepresented in clinical trials for heart failure, acute coronary syndrome

While women are equally or overrepresented in clinical trials for hypertension, atrial fibrillation (AFib) and pulmonary arterial hypertension, they are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome, according to a new study published in the Journal of the American College of Cardiology.